251 related articles for article (PubMed ID: 19784574)
1. Design, synthesis, and biological evaluation of phenylpropanamides as novel transient receptor potential vanilloid 1 antagonists.
Li FN; Kim NJ; Nam YH; Kim SH; Seo SY; Jeong YS; Kim SY; Park YH; Suh YG
Arch Pharm Res; 2009 Sep; 32(9):1201-10. PubMed ID: 19784574
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel diarylalkyl amides as TRPV1 antagonists.
Li FN; Kim NJ; Paek SM; Kwon DY; Min KH; Jeong YS; Kim SY; Park YH; Kim HD; Park HG; Suh YG
Bioorg Med Chem; 2009 May; 17(10):3557-67. PubMed ID: 19398205
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of B-region modified diarylalkyl amide analogues as novel TRPV1 antagonists.
Han YT; Yang SM; Wang XY; Li FN
Arch Pharm Res; 2014 Apr; 37(4):440-51. PubMed ID: 23943439
[TBL] [Abstract][Full Text] [Related]
4. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid.
El Kouhen R; Surowy CS; Bianchi BR; Neelands TR; McDonald HA; Niforatos W; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2005 Jul; 314(1):400-9. PubMed ID: 15837819
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structural optimization of multiple H-bonding region of diarylalkyl (thio)amides as novel TRPV1 antagonists.
Li FN; Kim NJ; Chang DJ; Jang J; Jang H; Jung JW; Min KH; Jeong YS; Kim SY; Park YH; Kim HD; Park HG; Suh YG
Bioorg Med Chem; 2009 Dec; 17(24):8149-60. PubMed ID: 19897373
[TBL] [Abstract][Full Text] [Related]
6. Binding of [(3)H]A-778317 to native transient receptor potential vanilloid-1 (TRPV1) channels in rat dorsal root ganglia and spinal cord.
Bianchi BR; El Kouhen R; Chen J; Puttfarcken PS
Eur J Pharmacol; 2010 May; 633(1-3):15-23. PubMed ID: 20153316
[TBL] [Abstract][Full Text] [Related]
7. Novel potent antagonists of transient receptor potential channel, vanilloid subfamily member 1: structure-activity relationship of 1,3-diarylalkyl thioureas possessing new vanilloid equivalents.
Suh YG; Lee YS; Min KH; Park OH; Kim JK; Seung HS; Seo SY; Lee BY; Nam YH; Lee KO; Kim HD; Park HG; Lee J; Oh U; Lim JO; Kang SU; Kil MJ; Koo JY; Shin SS; Joo YH; Kim JK; Jeong YS; Kim SY; Park YH
J Med Chem; 2005 Sep; 48(18):5823-36. PubMed ID: 16134949
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists.
Xi N; Bo Y; Doherty EM; Fotsch C; Gavva NR; Han N; Hungate RW; Klionsky L; Liu Q; Tamir R; Xu S; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2005 Dec; 15(23):5211-7. PubMed ID: 16203144
[TBL] [Abstract][Full Text] [Related]
9. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.
Norman MH; Zhu J; Fotsch C; Bo Y; Chen N; Chakrabarti P; Doherty EM; Gavva NR; Nishimura N; Nixey T; Ognyanov VI; Rzasa RM; Stec M; Surapaneni S; Tamir R; Viswanadhan VN; Treanor JJ
J Med Chem; 2007 Jul; 50(15):3497-514. PubMed ID: 17585749
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of indole-based peptoids as potent noncompetitive antagonists of transient receptor potential vanilloid 1.
Quintanar-Audelo M; Fernández-Carvajal A; Van Den Nest W; Carreño C; Ferrer-Montiel A; Albericio F
J Med Chem; 2007 Nov; 50(24):6133-43. PubMed ID: 17985859
[TBL] [Abstract][Full Text] [Related]
11. In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.
Perner RJ; DiDomenico S; Koenig JR; Gomtsyan A; Bayburt EK; Schmidt RG; Drizin I; Zheng GZ; Turner SC; Jinkerson T; Brown BS; Keddy RG; Lukin K; McDonald HA; Honore P; Mikusa J; Marsh KC; Wetter JM; George KS; Jarvis MF; Faltynek CR; Lee CH
J Med Chem; 2007 Jul; 50(15):3651-60. PubMed ID: 17583335
[TBL] [Abstract][Full Text] [Related]
12. Characterization of A-425619 at native TRPV1 receptors: a comparison between dorsal root ganglia and trigeminal ganglia.
McDonald HA; Neelands TR; Kort M; Han P; Vos MH; Faltynek CR; Moreland RB; Puttfarcken PS
Eur J Pharmacol; 2008 Oct; 596(1-3):62-9. PubMed ID: 18755179
[TBL] [Abstract][Full Text] [Related]
13. Direct activation of transient receptor potential vanilloid 1(TRPV1) by diacylglycerol (DAG).
Woo DH; Jung SJ; Zhu MH; Park CK; Kim YH; Oh SB; Lee CJ
Mol Pain; 2008 Oct; 4():42. PubMed ID: 18826653
[TBL] [Abstract][Full Text] [Related]
14. Contribution of transient receptor potential vanilloid subtype 1 to the analgesic and antihyperalgesic activity of nefopam in rodents.
Verleye M; Gillardin JM
Pharmacology; 2009; 83(2):116-21. PubMed ID: 19096234
[TBL] [Abstract][Full Text] [Related]
15. [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
Bianchi BR; El Kouhen R; Neelands TR; Lee CH; Gomtsyan A; Raja SN; Vaidyanathan SN; Surber B; McDonald HA; Surowy CS; Faltynek CR; Moreland RB; Jarvis MF; Puttfarcken PS
J Pharmacol Exp Ther; 2007 Oct; 323(1):285-93. PubMed ID: 17660385
[TBL] [Abstract][Full Text] [Related]
16. Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility.
Wang X; Chakrabarti PP; Ognyanov VI; Pettus LH; Tamir R; Tan H; Tang P; Treanor JJ; Gavva NR; Norman MH
Bioorg Med Chem Lett; 2007 Dec; 17(23):6539-45. PubMed ID: 17937985
[TBL] [Abstract][Full Text] [Related]
17. Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine.
Sadofsky LR; Campi B; Trevisani M; Compton SJ; Morice AH
Exp Lung Res; 2008 Dec; 34(10):681-93. PubMed ID: 19085565
[TBL] [Abstract][Full Text] [Related]
18. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
Ognyanov VI; Balan C; Bannon AW; Bo Y; Dominguez C; Fotsch C; Gore VK; Klionsky L; Ma VV; Qian YX; Tamir R; Wang X; Xi N; Xu S; Zhu D; Gavva NR; Treanor JJ; Norman MH
J Med Chem; 2006 Jun; 49(12):3719-42. PubMed ID: 16759115
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.
Tamayo N; Liao H; Stec MM; Wang X; Chakrabarti P; Retz D; Doherty EM; Surapaneni S; Tamir R; Bannon AW; Gavva NR; Norman MH
J Med Chem; 2008 May; 51(9):2744-57. PubMed ID: 18386885
[TBL] [Abstract][Full Text] [Related]
20. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.
Doherty EM; Fotsch C; Bannon AW; Bo Y; Chen N; Dominguez C; Falsey J; Gavva NR; Katon J; Nixey T; Ognyanov VI; Pettus L; Rzasa RM; Stec M; Surapaneni S; Tamir R; Zhu J; Treanor JJ; Norman MH
J Med Chem; 2007 Jul; 50(15):3515-27. PubMed ID: 17585750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
